(ASIX) AdvanSix - Ratings and Ratios
Nylon, Caprolactam, Fertilizer, Acetone, Intermediates
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.70% |
| Yield on Cost 5y | 3.54% |
| Yield CAGR 5y | 5.83% |
| Payout Consistency | 99.0% |
| Payout Ratio | 29.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 38.9% |
| Value at Risk 5%th | 61.2% |
| Relative Tail Risk | -4.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -53.77 |
| CAGR/Max DD | -0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.565 |
| Beta | 1.110 |
| Beta Downside | 0.818 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.97% |
| Mean DD | 34.23% |
| Median DD | 35.68% |
Description: ASIX AdvanSix December 25, 2025
AdvanSix Inc. (NYSE: ASIX) is a U.S.–based specialty chemicals producer that manufactures and sells polymer resins and related intermediates. Its core product line includes Nylon 6 resin, caprolactam (the primary feedstock for Nylon 6), and a suite of bulk chemicals such as ammonium sulfate fertilizer, acetone, phenol, cyclohexanone, and specialty amines.
The company markets its chemicals under several brand families-including Aegis, Sulf-N, Nadone, Naxol, and EZ-Blox-and reaches customers both directly and through a network of distributors in domestic and international markets. Its product mix serves end-users in automotive, textiles, packaging, coatings, and agricultural sectors.
Recent operating data (FY 2023) show net sales of roughly **$1.6 billion** with an adjusted EBITDA margin near **12 %**, reflecting the higher-margin profile of its Nylon 6 business. Caprolactam production capacity stands at about **1.2 million metric tons**, positioning AdvanSix as one of the largest U.S. producers, while its fertilizer segment contributes roughly **15 %** of total revenue.
Key economic drivers for AdvanSix include: (1) the global Nylon 6 demand growth of **~4 % CAGR**, propelled by lightweighting trends in automotive and increased packaging needs; (2) natural-gas-linked feedstock pricing, which can swing EBITDA margins by several percentage points; and (3) U.S. chemical capacity constraints that have historically supported pricing power for domestically produced caprolactam and related intermediates.
If you’re looking to deepen your quantitative analysis of AdvanSix’s valuation metrics, a quick look at ValueRay’s model can provide a useful benchmark for further research.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (52.4m TTM) > 0 and > 6% of Revenue (6% = 89.5m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 0.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.09% (prev 6.41%; Δ 1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 123.3m > Net Income 52.4m (YES >=105%, WARN >=100%) |
| Net Debt (382.9m) to EBITDA (132.3m) ratio: 2.90 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.2m) change vs 12m ago 0.16% (target <= -2.0% for YES) |
| Gross Margin 9.98% (prev 10.20%; Δ -0.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 93.25% (prev 104.0%; Δ -10.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.55 (EBITDA TTM 132.3m / Interest Expense TTM 8.29m) >= 6 (WARN >= 3) |
Altman Z'' 2.81
| (A) 0.07 = (Total Current Assets 455.0m - Total Current Liabilities 334.3m) / Total Assets 1.69b |
| (B) 0.40 = Retained Earnings (Balance) 670.3m / Total Assets 1.69b |
| (C) 0.03 = EBIT TTM 54.3m / Avg Total Assets 1.60b |
| (D) 0.78 = Book Value of Equity 676.4m / Total Liabilities 870.1m |
| Total Rating: 2.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.10
| 1. Piotroski 3.50pt |
| 2. FCF Yield 0.01% |
| 3. FCF Margin 0.01% |
| 4. Debt/Equity 0.50 |
| 5. Debt/Ebitda 2.90 |
| 6. ROIC - WACC (= -1.14)% |
| 7. RoE 6.53% |
| 8. Rev. Trend -55.14% |
| 9. EPS Trend -43.22% |
What is the price of ASIX shares?
Over the past week, the price has changed by +1.11%, over one month by +13.22%, over three months by -9.73% and over the past year by -37.26%.
Is ASIX a buy, sell or hold?
What are the forecasts/targets for the ASIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28 | 61.8% |
| Analysts Target Price | 28 | 61.8% |
| ValueRay Target Price | 15.3 | -11.8% |
ASIX Fundamental Data Overview December 27, 2025
P/E Trailing = 8.4375
P/S = 0.3082
P/B = 0.5618
Beta = 1.721
Revenue TTM = 1.49b USD
EBIT TTM = 54.3m USD
EBITDA TTM = 132.3m USD
Long Term Debt = 250.0m USD (from longTermDebt, last quarter)
Short Term Debt = 41.7m USD (from shortTermDebt, last quarter)
Debt = 406.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 382.9m USD (from netDebt column, last quarter)
Enterprise Value = 818.1m USD (435.2m + Debt 406.6m - CCE 23.7m)
Interest Coverage Ratio = 6.55 (Ebit TTM 54.3m / Interest Expense TTM 8.29m)
FCF Yield = 0.01% (FCF TTM 108.0k / Enterprise Value 818.1m)
FCF Margin = 0.01% (FCF TTM 108.0k / Revenue TTM 1.49b)
Net Margin = 3.52% (Net Income TTM 52.4m / Revenue TTM 1.49b)
Gross Margin = 9.98% ((Revenue TTM 1.49b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 6.78% (prev 14.32%)
Tobins Q-Ratio = 0.48 (Enterprise Value 818.1m / Total Assets 1.69b)
Interest Expense / Debt = 0.57% (Interest Expense 2.32m / Debt 406.6m)
Taxrate = -52.57% (out of range, set to none) (909.0k / -1.73m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.36 (Total Current Assets 455.0m / Total Current Liabilities 334.3m)
Debt / Equity = 0.50 (Debt 406.6m / totalStockholderEquity, last quarter 818.2m)
Debt / EBITDA = 2.90 (Net Debt 382.9m / EBITDA 132.3m)
Debt / FCF = 3546 (out of range, set to none) (Net Debt 382.9m / FCF TTM 108.0k)
Total Stockholder Equity = 802.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.11% (Net Income 52.4m / Total Assets 1.69b)
RoE = 6.53% (Net Income TTM 52.4m / Total Stockholder Equity 802.7m)
RoCE = 5.16% (EBIT 54.3m / Capital Employed (Equity 802.7m + L.T.Debt 250.0m))
RoIC = 4.08% (EBIT 54.3m / (Assets 1.69b - Curr.Liab 334.3m - Cash 23.7m))
WACC = 5.22% (E(435.2m)/V(841.8m) * Re(10.10%) + (debt cost/tax rate unavailable))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.62%
[DCF Debug] Terminal Value 61.77% ; FCFE base≈108.0k ; Y1≈70.9k ; Y5≈32.4k
Fair Price DCF = 0.02 (DCF Value 470.7k / Shares Outstanding 26.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -43.22 | EPS CAGR: -32.33% | SUE: -0.81 | # QB: 0
Revenue Correlation: -55.14 | Revenue CAGR: -3.26% | SUE: 0.06 | # QB: 0
EPS next Year (2026-12-31): EPS=3.00 | Chg30d=-0.850 | Revisions Net=+0 | Growth EPS=+31.6% | Growth Revenue=+4.6%
Additional Sources for ASIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle